Unknown NA INTERVENTIONAL 2-arm NCT00518557

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis (TACE HCC)

Combination Treatment of TACE With Recombinant Human Endostatin Administrated Via Hepatic Artery in Hepatocellular Carcinoma

Sponsor: Southeast University, China

Conditions Hepatocellular Carcinoma

Interventions Transcatheter Arterial Chemoembolization

Updated 5 times since 2017 Last updated: Jan 21, 2009 Started: Apr 30, 2007 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Southeast University, China and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Southeast University, China

Data source: Southeast University, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China